6855.HK Stock Analysis
68
Uncovered
Ascentage Pharma Group International is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company, which engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 600 full-time employees. The company went IPO on 2019-10-28. The firm focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The firm's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The firm conducts businesses within the domestic market and to overseas markets, including the United States.